ERBB2 and ovarian carcinoma: A humanised monoclonal antibody that binds to the extracellular domain of Her2 and blocks its heterodimerisation with ErbB3 and other EGFR family members, pertuzumab (2C4), has been explored in clinical trials in ovarian cancer.